A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy
暂无分享,去创建一个
Kai Fu | Javeed Iqbal | Jan Delabie | Randy D Gascoyne | Min Li | Timothy C Greiner | Zhongfeng Liu | Andreas Rosenwald | Elias Campo | L. Staudt | A. Rosenwald | W. Chan | T. Greiner | D. Weisenburger | K. Fu | W. Choi | Lynette M. Smith | C. Hans | J. Vose | R. Gascoyne | E. Campo | L. Rimsza | G. Ott | G. Lenz | E. Jaffe | J. Delabie | M. Piris | R. Braziel | A. Banham | J. Iqbal | H. Geng | D. Jaye | Louis M Staudt | Julie M Vose | Wing C Chan | German Ott | Georg Lenz | Lynette M Smith | Lisa M Rimsza | Miguel A Piris | Elaine S Jaffe | Rita M Braziel | Dennis D Weisenburger | Huimin Geng | Christine P Hans | Alison H Banham | William W L Choi | David L Jaye | Zhongfeng Liu | Min Li
[1] I. Lossos,et al. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. , 2007, Blood.
[2] A. Rosenwald,et al. Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. , 2008, Blood.
[3] R. Rosenquist,et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis , 2005, Modern Pathology.
[4] M. Møller,et al. Profiling of diffuse large B‐cell lymphoma by immunohistochemistry: identification of prognostic subgroups , 2007, European journal of haematology.
[5] G. Saglio,et al. Molecular pathogenesis of diffuse large B-cell lymphoma , 2009 .
[6] W. Chan,et al. Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas. , 2008, Blood.
[7] L. Staudt,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.
[8] W. Chan,et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] C J L M Meijer,et al. Immunohistochemical profiling based on Bcl‐2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma , 2006, The Journal of pathology.
[10] L. Staudt,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[11] S. Barrans,et al. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. , 2004, Blood.
[12] L. Rimsza,et al. Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival. , 2006, Archives of pathology & laboratory medicine.
[13] Carlos S. Moreno,et al. MTA3, a Mi-2/NuRD Complex Subunit, Regulates an Invasive Growth Pathway in Breast Cancer , 2003, Cell.
[14] T. Molina,et al. Germinal Center Phenotype Determined by Immunohistochemistry on Tissue Microarray Does Not Correlate with Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy in the Randomized Trial LNH98-5. A GELA Study. , 2007 .
[15] L. Staudt,et al. Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.
[16] R. Gascoyne,et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] P. Gaulard,et al. Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. , 2003, The American journal of pathology.
[18] Chung-Che Chang,et al. Immunohistochemical Expression Patterns of Germinal Center and Activation B-cell Markers Correlate With Prognosis in Diffuse Large B-cell Lymphoma , 2004, The American journal of surgical pathology.
[19] Robert Tibshirani,et al. HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. , 2003, Blood.
[20] C Fidler,et al. The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. , 2001, Cancer research.
[21] Andrew Lister,et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] D. Macdonald,et al. Absence of cyclin‐D2 and Bcl‐2 expression within the germinal centre type of diffuse large B‐cell lymphoma identifies a very good prognostic subgroup of patients , 2007, Histopathology.
[23] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[24] Emili Montserrat,et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. , 2003, Blood.
[25] E. Schuuring,et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] K. Amara,et al. Presence of simian virus 40 in diffuse large B-cell lymphomas in Tunisia correlates with germinal center B-cell immunophenotype, t(14;18) translocation, and P53 accumulation , 2008, Modern Pathology.
[27] Adrian Wiestner,et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[28] Ramón Bosch,et al. Building an outcome predictor model for diffuse large B-cell lymphoma. , 2004, The American journal of pathology.
[29] N. Harris,et al. Expression of bcl-6 and CD10 in Primary Mediastinal Large B-Cell Lymphoma: Evidence for Derivation From Germinal Center B Cells? , 2001, The American journal of surgical pathology.
[30] T. Golub,et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. , 2003, Blood.
[31] J. D. Capra,et al. Identification of centerin: a novel human germinal center B cell‐restricted serpin , 2000, European journal of immunology.
[32] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[33] Carl Blomqvist,et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. , 2007, Blood.
[34] U. Martens,et al. Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] M. Calaminici,et al. CD23 expression in mediastinal large B‐cell lymphomas , 2004, Histopathology.
[36] P. de Paepe,et al. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] R. Gascoyne,et al. Expression of TRAF1 and Nuclear c-Rel Distinguishes Primary Mediastinal Large Cell Lymphoma From Other Types of Diffuse Large B-cell Lymphoma , 2007, The American journal of surgical pathology.
[38] L. Staudt,et al. Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma , 2003, The Journal of experimental medicine.
[39] S. Barrans,et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. , 2002, Blood.
[40] Weiguo Shu,et al. Characterization of a New Subfamily of Winged-helix/Forkhead (Fox) Genes That Are Expressed in the Lung and Act as Transcriptional Repressors* , 2001, The Journal of Biological Chemistry.
[41] C. Copie-Bergman,et al. Respective prognostic values of germinal center phenotype and early (18)fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma. , 2007, Haematologica.
[42] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[43] H Stein,et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. , 2000, Blood.
[44] L. Staudt,et al. Two newly characterized germinal center B-cell-associated genes, GCET1 and GCET2, have differential expression in normal and neoplastic B cells. , 2003, The American journal of pathology.
[45] Robert Tibshirani,et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.